Literature DB >> 31746224

Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.

Carolyn E Haunschild1, Krishnansu S Tewari2,3.   

Abstract

On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.

Entities:  

Keywords:  bevacizumab; biological therapy; clinical trials; gynecologic/ovarian

Mesh：

Substances：

Year:  2019        PMID： 31746224      PMCID： PMC7036749          DOI： 10.2217/fon-2019-0042

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  94 in total

1.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Authors:  Martin R Stockler; Felix Hilpert; Michael Friedlander; Madeleine T King; Lari Wenzel; Chee Khoon Lee; Florence Joly; Nikolaus de Gregorio; José Angel Arranz; Mansoor Raza Mirza; Roberto Sorio; Ulrich Freudensprung; Vesna Sneller; Gill Hales; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).

Authors:  Antonio Gonzalez-Martin; Laurence Gladieff; Bengt Tholander; Daniel Stroyakovsky; Martin Gore; Giovanni Scambia; Ana Oaknin; Vesna Sneller; Ulrich Freudensprung; Sandro Pignata
Journal:  Eur J Cancer       Date:  2014-01-10       Impact factor: 9.162

3.  Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Authors:  Leslie M Randall; Michael W Sill; Robert A Burger; Bradley J Monk; Barbara Buening; Joel I Sorosky
Journal:  Gynecol Oncol       Date:  2011-12-01       Impact factor: 5.482

4.  An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.

Authors:  Olivier Mir; Romain Coriat; Laure Cabanes; Stanislas Ropert; Bertrand Billemont; Jérôme Alexandre; Jean-Philippe Durand; Jean-Marc Treluyer; Bertrand Knebelmann; François Goldwasser
Journal:  Oncologist       Date:  2011-08-01

5.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

6.  CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.

Authors:  Chaan S Ng; Zheng Zhang; Susanna I Lee; Helga S Marques; Kyle Burgers; Feng Su; Joseph Bauza; Robert S Mannel; Joan L Walker; Warner King Huh; Stephen C Rubin; Paul DiSilvestro; Lainie P Martin; John K Chan; Michael A Bookman; Robert L Coleman; Ting-Yim Lee
Journal:  Clin Cancer Res       Date:  2017-02-07       Impact factor: 12.531

7.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Authors:  Sandro Pignata; Giovanni Scambia; Dionyssios Katsaros; Ciro Gallo; Eric Pujade-Lauraine; Sabino De Placido; Alessandra Bologna; Beatrice Weber; Francesco Raspagliesi; Pierluigi Benedetti Panici; Gennaro Cormio; Roberto Sorio; Maria Giovanna Cavazzini; Gabriella Ferrandina; Enrico Breda; Viviana Murgia; Cosimo Sacco; Saverio Cinieri; Vanda Salutari; Caterina Ricci; Carmela Pisano; Stefano Greggi; Rossella Lauria; Domenica Lorusso; Claudia Marchetti; Luigi Selvaggi; Simona Signoriello; Maria Carmela Piccirillo; Massimo Di Maio; Francesco Perrone
Journal:  Lancet Oncol       Date:  2014-02-28       Impact factor: 41.316

Review 8.  Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.

Authors:  B J Monk; E Pujade-Lauraine; R A Burger
Journal:  Ann Oncol       Date:  2013-12       Impact factor: 32.976

9.  Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.

Authors:  Toshiki Iwai; MasamichI Sugimoto; Suguru Harada; Keigo Yorozu; Mitsue Kurasawa; Kaname Yamamoto
Journal:  Oncol Rep       Date:  2016-06-22       Impact factor: 3.906

10.  The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.

Authors:  Alison Backen; Andrew G Renehan; Andrew R Clamp; Carlo Berzuini; Cong Zhou; Amit Oza; Selina Bannoo; Stefan J Scherer; Rosamonde E Banks; Caroline Dive; Gordon C Jayson
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531
View more
  11 in total

1.  Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort.

Authors:  Irena Conic; Bojan Nedovic; Slavica Stojnev; Ilinka Todorovska; Aleksandra Dimitrijevic; Miljan Krstic; Ivana Djordjevic; Biljana Djordjevic
Journal:  Medicina (Kaunas)       Date:  2022-04-27       Impact factor: 2.948

2.  Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer.

Authors:  Jo-Ni Hung; Shih-Tien Hsu; Lou Sun; Sheau-Feng Hwang; Chih-Ku Liu; Yu-Hsiang Shih; Ming-Jer Chen; Jun-Sing Wang; Chien-Hsing Lu
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

Review 3.  Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.

Authors:  Hongyan Cheng; Junjun Yang; Huixin Liu; Yang Xiang
Journal:  Arch Gynecol Obstet       Date:  2021-05-21       Impact factor: 2.344

4.  Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.

Authors:  Oladapo O Yeku; Thapi Dharma Rao; Ian Laster; Artem Kononenko; Terence J Purdon; Pei Wang; Ziyou Cui; Hong Liu; Renier J Brentjens; David Spriggs
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

5.  Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature.

Authors:  Daniel de Castilho da Silva; Guilherme Di Camillo Orfali; Maycon Giovani Santana; Jessica Kaoru Yamamoto Palma; Isabella Ramos de Oliveira Assunção; Isadora Moraes Marchesi; Ana Yoshie Kitagawa Grizotto; Natália Peres Martinez; Simone Felliti; José Aires Pereira; Denise Gonçalves Priolli
Journal:  Oncotarget       Date:  2022-02-08

6.  The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients.

Authors:  Longhai Li; Kai Jiang; Dongpeng Li; Dongxiao Li; Zitong Fan; Guosheng Dai; Sheng Tu; Xiangyu Liu; Guangyou Wei
Journal:  Front Oncol       Date:  2021-10-08       Impact factor: 6.244

7.  Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland.

Authors:  Jingxue Zhang; Xuejing Yan; Rui Liu; Shen Wu; Qian Liu; Jing Li; Jianmin Ma
Journal:  Cancer Manag Res       Date:  2022-03-06       Impact factor: 3.989

8.  Axillary lymph-node metastases as the primary presentation of high-grade serous ovarian carcinoma: A case report.

Authors:  Monire Mirzaei; Abbas Eshraghi; Mahdiieh Ghoddoosi; Maedeh Alsadat Fatemi; Azhar Eshraghi; Sara Shenavaei; Danial Fazilat-Panah
Journal:  Clin Case Rep       Date:  2022-04-14

Review 9.  Immunotherapy in Ovarian Cancer.

Authors:  Natalia Siminiak; Rafał Czepczyński; Mikołaj Piotr Zaborowski; Dariusz Iżycki
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-08-09       Impact factor: 3.831

Review 10.  Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies.

Authors:  Yi-Chao Wang; Jing-Yan Tian; Ying-Ying Han; Yun-Fei Liu; Si-Yao Chen; Feng-Jun Guo
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.